Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 13/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5649732 | 0.98 | HTR3A (0.44) | HTR3ACHRNA7GAASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL5298314 | 0.85 | KAT2B (0.38) | HTR3ACHRNA7GAASMN1; SMN2MEN1 | |
| SCHEMBL12005492 | 0.82 | CHRNA7 (0.46) | HTR3ACHRNA7GAASMN1; SMN2MEN1 | |
| SCHEMBL3928547 | 0.81 | CHRNA7 (0.59) | HTR3ACHRNA7GAA | |
| SCHEMBL13444722 | 0.81 | CHRNA7 (0.59) | HTR3ACHRNA7GAA | |
| SCHEMBL5400969 | 0.81 | CHRNA7 (0.55) | HTR3ACHRNA7GAASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL5649317 | 0.79 | CHRNA7 (0.53) | HTR3ACHRNA7GAASMN1; SMN2MEN1 | |
| SCHEMBL5407108 | 0.79 | CHRNA7 (0.54) | HTR3ACHRNA7GAAALOX15TSHR | |
| SCHEMBL5404570 | 0.78 | CHRNA7 (0.43) | HTR3ACHRNA7GAASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL5652086 | 0.78 | CHRNA7 (0.52) | HTR3ACHRNA7GAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| US-7160876-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | HTR3A 138/4885CHRNA7 2/4885GAA 1807/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | HTR3A 5/4885CHRNA7 144/4885GAA 4490/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | HTR3A 138/4885CHRNA7 2/4885GAA 1807/4885 |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA1, CHRNA2, CHRM2 | HTR3A 194/4885CHRNA7 8/4885GAA 1733/4885 |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | HTR3A 71/4885CHRNA7 11/4885GAA 1774/4885 |
| US-20070066592-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | HTR3A 134/4885CHRNA7 2/4885GAA 1752/4885 |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | HTR3A 134/4885CHRNA7 2/4885GAA 1752/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | HTR3A 39/4885CHRNA7 1/4885GAA 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.